PictorLabs develops AI-powered virtual staining software that generates digitally stained histology slides in minutes, eliminating the need for traditional toxic reagents. Its technology aims to shorten turnaround times while increasing consistency and throughput for pathology labs used in research, pharma, and clinical applications. The company was spun off from the UCLA Colleges of Engineering and Medicine and is positioned to drive the digital transformation of histopathology. PictorLabs plans to scale operations, expand market reach, and accelerate adoption of virtual staining in clinical and research settings. Financially, PictorLabs announced a $30 million Series B led by Insight Partners with continued participation from M Ventures. The company intends to use the capital to advance its technology, grow the team, and broaden commercial deployment to improve diagnostic speed and sustainability in laboratory practices. PictorLabs provides AI virtual staining technology that applies deep learning to generate near-instantaneous in silico stains from a single unstained tissue sample. Its proprietary platform can produce an unlimited number of virtual stains indistinguishable from analogous chemical stains. The company is developing products that replicate standard-of-care stains and specialized virtual biomarker stains for indications with high demand for accelerated diagnostics. PictorLabs intends to expand its biomarker portfolio, develop novel products, grow its talent base, and build out its corporate infrastructure with the new funding. It established a partnership with Charles River Laboratories to reduce water consumption and chemical waste by adopting virtual staining as part of sustainability initiatives. Founded in 2019 and based in Los Angeles, the company aims to accelerate clinical research and improve patient outcomes through its technology.

Total raised

$45M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2024